What actually shows up in a retatrutide before and after?

The Phase 2 obesity trial measured body weight, waist-related metabolic markers, liver fat by MRI-PDFF, blood pressure, triglycerides, and, in participants with type 2 diabetes, A1C, all trending favorably alongside the weight loss. It did not standardize or publish before-and-after photographs, so the visual "after" you see online is anecdotal, not a trial-reported outcome.

How long before a retatrutide before and after is noticeable?

The Phase 2 trial's earliest reported timepoint was 24 weeks, where the 12 mg group averaged 17.5% mean weight loss, rising to 24.2% at 48 weeks. Community and anecdotal reports commonly describe early appetite and clothing-fit changes inside the first one to two months, well before a 24-week trial figure applies, but that earlier pattern is not itself a published trial endpoint.

Why do two people's retatrutide before and afters look so different at the same number of weeks?

Dose reached, titration speed, starting body weight, adherence, and normal biological variability all scatter individual results around the trial mean. Someone at 4 mg and someone at 12 mg on the same calendar week are not on the same point of the dose-response curve, even though both are technically "on retatrutide."

Are the dramatic before-and-after photos online realistic?

They are usually real but self-selected. Photos that circulate widely tend to come from strong responders at or near the 12 mg dose, months into a protocol, photographed under favorable lighting and posture. The Phase 2 trial's own responder data show a wide range of outcomes, from 8.7% at the lowest dose to 24.2% at the highest, so a single viral photo is not a representative baseline.

Does the scale or the mirror change first?

Appetite and meal-size changes are typically the earliest-noticed shift, often before a visible photo difference. Facial and midsection changes are commonly reported as the first visually apparent signals, while total-body composition change accumulates more gradually as weight loss continues across the trial's 24- and 48-week windows.

Should I take my own before-and-after photos?

A consistent photo taken under the same lighting, pose, and time of day at fixed intervals is a more reliable personal record than a single before-and-after comparison, because it controls for the variables (posture, hydration, lighting) that make random photos misleading.

Retatrutide Before and After: What the Trial Data Says Actually Changes

Quick answer

Retatrutide's Phase 2 trial did not publish standardized before-and-after photographs. What it measured was body weight (17.5% mean loss at 24 weeks, 24.2% at 48 weeks on the 12 mg dose), plus liver fat, blood pressure, triglycerides, and A1C in the diabetes subgroup, all trending favorably. ^[1]
The viral photos people call "before and after" are real but self-selected toward strong responders at higher doses, later timepoints, and favorable lighting, not a representative sample. ^[1]
Individual results scatter widely by dose: the trial's own range ran from 8.7% mean loss at 1 mg to 24.2% at 12 mg, at the same 48-week mark. ^[1]
A consistent, fixed-interval personal photo plus the trial's own timepoints is a more honest before-and-after record than comparing yourself to a single photo found online.

Type "retatrutide before and after" into a search bar and the results are almost entirely photographs and forum threads, not trial data. That gap is worth naming up front: the Phase 2 obesity trial that established retatrutide's efficacy measured weight, waist-related metrics, liver fat, blood pressure, triglycerides, and glycemic control in participants with type 2 diabetes. ^[1] It did not publish a standardized photo set. Every "before and after" image circulating online is a self-reported, uncontrolled anecdote layered on top of real trial data, and the two are easy to conflate.

This guide separates what the trial actually measured from what a photo can and cannot tell you, walks through what commonly changes and roughly when, and gives an honest framework for reading your own results, or someone else's, without over- or under-reading a single image.

What a "before and after" is actually built from

What the trial measured vs. what a photo shows

Signal	Trial-measured	What a photo adds
Body weight	Yes, 17.5% at 24 weeks, 24.2% at 48 weeks (12 mg)	Confirms direction, not magnitude
Waist and body composition trends	Reported alongside weight loss	Visual proxy, affected by posture and clothing
Liver fat (MRI-PDFF)	Yes, reduced alongside weight loss	Not visible in a photo at all
Blood pressure and triglycerides	Yes, improved alongside weight loss	Not visible in a photo at all
A1C (type 2 diabetes subgroup)	Yes, improved	Not visible in a photo at all
Facial or midsection appearance	Not a trial endpoint	The most commonly shared, least standardized signal

Reading that table left to right is the point of this guide. The number that shows up in a headline, the trial's mean weight loss, is one line among several the trial actually tracked, and a photo captures none of the rows below it. ^[1]

I started taking a photo on the first of every month, same spot against the same wall in my apartment, same gray t-shirt, morning light. I did it mostly out of boredom the first time, not because I expected it to matter.

Months one and two looked identical to me. I remember being frustrated, scrolling through photos other people had posted that looked more dramatic than mine at the same point. Month three was where I first noticed a real difference lining the photos up side by side, my face and collarbone mostly, not my stomach yet.

By month five the stack of photos told a clearer story than any single comparison would have. What I learned is that the trial's own numbers, a slow first stretch and a bigger change later, matched my photos almost exactly once I stopped comparing month two of my protocol to month five of someone else's.

— Miguel Torres, El Paso, TX

What commonly changes, and in roughly what order

Trial data establishes the weight and metabolic numbers. The order in which physical changes become visible is not something the Phase 2 trial standardized or reported, but it is a consistent enough pattern across community and clinical accounts of GLP-1-class compounds to describe honestly, labeled clearly as an observed pattern rather than a trial finding.

Appetite and meal size shift first, usually before any visible change, tracking rising plasma exposure through the titration schedule. ^[2]
Facial and neck fullness is commonly the earliest visually reported change, likely because facial fat responds early to a caloric deficit generally, not something specific to this compound's mechanism.
Midsection and waist changes tend to follow, becoming more apparent as cumulative loss builds through the trial's 12- to 24-week window.
Overall body composition, the "after" most photos are trying to capture, accumulates gradually and continues past the 24-week mark toward the 48-week endpoint, where the trial's own curve had not clearly plateaued. ^[1]

The metabolic "after" a photo cannot show

These are arguably the more clinically meaningful "after," and none of them show up in a mirror. A person whose photo looks similar month to month can still be accumulating real metabolic change underneath, particularly early in a protocol when body composition is shifting before the scale or a photo shows a dramatic difference. This is one reason the trial's own investigators tracked lab values and imaging rather than relying on visual assessment.

How much weight loss is behind a typical "after" photo

Retatrutide mean weight loss at 48 weeks, lowest vs. highest dose

Dose	Mean weight loss at 48 weeks	Source
1 mg	8.7%	Phase 2 ^[1]
12 mg	24.2%	Phase 2 ^[1]
Placebo	2.1%	Phase 2 ^[1]

Weight loss climbed in an orderly, dose-dependent progression between those two ends of the range, with the intermediate doses landing between them. ^[1] A photo alone cannot tell you which point on that progression someone is standing at. Two "after" photos taken at the same calendar week can represent close to a threefold difference in actual weight loss if one person reached 12 mg and the other is still at 1 mg, which is one reason comparing your own photo timeline to a stranger's is a weaker exercise than comparing your numbers to the trial's dose-matched figures. The full week-by-week shape of that curve, phase by phase, is covered in the week-by-week timeline guide, and the 3-month-specific reading is covered in the 3-month results guide.

Why viral before-and-after photos are not a representative baseline

Photos that circulate widely share a few things in common: they tend to feature strong responders, later timepoints, favorable lighting, and a flattering pose. None of that makes them fake, but it does make them selected rather than typical. The trial's own responder data show a real spread, not a single outcome: at 48 weeks, 100% of the 12 mg group reached at least 5% weight loss, 93% reached at least 10%, and 83% reached at least 15%, against 27%, 9%, and 2% on placebo. ^[1] That spread means most people are somewhere between "no visible change" and "the photo that goes viral," and the median experience is less dramatic than the most-shared one.

Common mistakes reading a before and after

Comparing your week 12 to someone else's week 24 or 48, which compares two different points on the same curve as if they were equivalent.
Comparing your dose to a dose you have not reached yet. A 4 mg "after" measured against a 12 mg headline number is comparing different rows of the table above. ^[1]
Treating a single photo as the verdict instead of a trend. Lighting, posture, hydration, and time of day can shift how a single photo reads more than a week of real change does.
Ignoring the metabolic "after." A flat-looking photo at 12 weeks can still sit on top of real, trial-consistent liver fat, blood pressure, or triglyceride improvement that a photo cannot capture. ^[1]
Reading water-weight fluctuation as fat regain, or a whoosh as sudden fat loss. Both are usually fluid shifts, not the underlying trend.

Documenting your own before and after honestly

None of this is medical advice, but a few practical habits make a personal photo record more useful than a single comparison shot:

Fix the variables: same spot, same lighting, same pose, same rough time of day, ideally the same morning routine each time.
Photograph on a fixed interval, such as monthly, rather than only when you feel like the change will be visible, which biases the record toward days that already look good.
Pair the photo with a number, whether that is weight, a waist measurement, or how clothing fits, so the visual record has a data point attached rather than standing alone.
Expect the early photos to look similar. The trial's own curve is gradual for the first several weeks while titration is still in progress, so a flat first month or two of photos is consistent with the published pattern, not a sign nothing is happening. ^[2]

How retatrutide's before and after compares to semaglutide and tirzepatide

Class comparison (separate trials, endpoint figures)

Compound	Receptors	Mean weight loss	Trial
Semaglutide	GLP-1	~15%	STEP 1 ^[5]
Tirzepatide	GLP-1 / GIP	~21%	SURMOUNT-1 ^[4]
Retatrutide	GLP-1 / GIP / glucagon	~24% (48 wk)	Phase 2 ^[1]

These come from separate trials with different populations, timeframes, and endpoints, not a single head-to-head study, so the comparison is directional rather than exact. The pattern, more receptor coverage associated with more mean loss, tracks the triple-agonist mechanism, covered in depth in how retatrutide's mechanism works. What it means for a before-and-after comparison across compounds is the same caution as within one compound: match the dose and the timepoint before comparing the photo.

Individual factors that shape your before and after

Dose reached. The single largest driver of where you land on the table above; a protocol still titrating is not comparable to one that reached 12 mg. ^[1]
Titration speed and adherence. The compound's roughly six-day half-life tolerates an occasional missed dose without zeroing exposure, but repeated gaps flatten the accumulation the trial's own dosing schedule depends on. ^[2]
Starting body weight. A larger starting weight generally produces a larger absolute change for the same percentage, which changes how dramatic a given percentage looks in a photo.
Biological variability. Even inside a controlled trial, responders spread across a real range rather than converging on one number, which is exactly why the responder-rate table above matters more than a single mean. ^[1]

Side effects during the transition from before to after

The stretch where visible change is building is also the stretch where trial-reported side effects concentrate. The dominant effects are gastrointestinal, nausea, diarrhea, constipation, and reduced appetite, dose-dependent and clustered during dose escalation. ^[1] Some participants also reported headache and, less commonly, dizziness during titration, and a skin-sensation effect called dysesthesia at higher doses. ^[1] If you are tracking a before-and-after timeline, the same weeks that are hardest on tolerability are usually the weeks where the least visible change has accumulated yet, which is worth knowing going in. The retatrutide headache guide and retatrutide hair loss guide cover two of the more commonly searched side-effect questions in more depth.

Why sourcing quality affects your own before and after

A before-and-after record only reflects the compound if the vial actually contains what the label says. An under-concentrated, degraded, or mislabeled product produces a real but muted version of the trial's curve, which can look like a disappointing "after" when the underlying issue is the source, not the compound. A batch-matched certificate of analysis, ideally backed by independent third-party testing, is the practical way to keep your own timeline comparable to the trial's. The buying guide and how a manufacturer gets vetted walk through what that verification actually looks like before you start your own before-and-after record.

Setting a realistic before-and-after timeline

Given everything above, the honest framework is: expect the first four to five weeks to look and feel the quietest, consistent with the compound's steady-state pharmacokinetics, expect the middle stretch through roughly week 24 to carry the steepest change the trial recorded, and expect the metabolic "after," not just the visual one, to keep accumulating toward the 48-week endpoint the trial had not yet seen plateau. ^[1] ^[2] A single early photo is not a verdict in either direction. The 1-month results guide and 3-month results guide go deeper on those two specific early checkpoints if you are trying to read where you stand right now.

Frequently asked questions

What actually shows up in a retatrutide before and after?: The Phase 2 obesity trial measured body weight, waist-related metabolic markers, liver fat by MRI-PDFF, blood pressure, triglycerides, and, in participants with type 2 diabetes, A1C, all trending favorably alongside the weight loss. It did not standardize or publish before-and-after photographs, so the visual "after" you see online is anecdotal, not a trial-reported outcome.
How long before a retatrutide before and after is noticeable?: The Phase 2 trial's earliest reported timepoint was 24 weeks, where the 12 mg group averaged 17.5% mean weight loss, rising to 24.2% at 48 weeks. Community and anecdotal reports commonly describe early appetite and clothing-fit changes inside the first one to two months, well before a 24-week trial figure applies, but that earlier pattern is not itself a published trial endpoint.
Why do two people's retatrutide before and afters look so different at the same number of weeks?: Dose reached, titration speed, starting body weight, adherence, and normal biological variability all scatter individual results around the trial mean. Someone at 4 mg and someone at 12 mg on the same calendar week are not on the same point of the dose-response curve, even though both are technically "on retatrutide."
Are the dramatic before-and-after photos online realistic?: They are usually real but self-selected. Photos that circulate widely tend to come from strong responders at or near the 12 mg dose, months into a protocol, photographed under favorable lighting and posture. The Phase 2 trial's own responder data show a wide range of outcomes, from 8.7% at the lowest dose to 24.2% at the highest, so a single viral photo is not a representative baseline.
Does the scale or the mirror change first?: Appetite and meal-size changes are typically the earliest-noticed shift, often before a visible photo difference. Facial and midsection changes are commonly reported as the first visually apparent signals, while total-body composition change accumulates more gradually as weight loss continues across the trial's 24- and 48-week windows.
Should I take my own before-and-after photos?: A consistent photo taken under the same lighting, pose, and time of day at fixed intervals is a more reliable personal record than a single before-and-after comparison, because it controls for the variables (posture, hydration, lighting) that make random photos misleading.

Glossary

MRI-PDFF: Magnetic resonance imaging proton density fat fraction, an imaging method used in the Phase 2 trial to measure liver fat, one of the metabolic outcomes tracked alongside weight.
Responder rate: The percentage of participants crossing a weight-loss threshold, such as 10% or 15%, a more informative figure than the group mean when reading how typical a given outcome is.
Titration: Stepwise dose escalation over several weeks, used to improve tolerability as exposure accumulates before the target dose is reached.
Steady state: The point at which plasma concentration stabilizes on a fixed weekly dose, reached in roughly 4 to 5 weeks for retatrutide's approximately 6-day half-life.
Dysesthesia: An abnormal skin sensation reported as a side effect at higher retatrutide doses in the Phase 2 trial.

References

Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526.
Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: preclinical and clinical characterization. Cell Metabolism. 2022;34(9):1234-1247.
Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b trial. The Lancet. 2022;400(10366):1869-1881.
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.

For research and educational purposes only. Not medical advice. Trial figures describe published clinical studies; the described order and timing of visible physical changes reflects a commonly reported pattern, not a standardized trial endpoint. Cross-compound comparisons are drawn from separate trials, not a single head-to-head study. Retatrutide is investigational and is not approved for human use.